CDC Report Highlights Low Use of COVID-19 Antivirals Among People 65 and Older

Why It Matters

Low antiviral uptake among seniors risks higher hospitalizations and deaths, weakening public‑health progress toward endemic COVID‑19 management.

Key Takeaways

• Only 16‑23% of seniors got antivirals during low case periods
• Prescription rates rose to 37‑38% when cases surged
• Adults 75+ more likely to receive treatment than 65‑74
• CDC urges better provider and patient awareness of antivirals
• Low antiviral uptake may increase severe outcomes among older adults

Pulse Analysis

The CDC’s latest surveillance data underscores a persistent gap between the availability of oral COVID‑19 antivirals and their real‑world use among the nation’s oldest adults. Although drugs such as Paxlovid and Lagevrio have received full FDA approval and are stocked in most health‑system formularies, the report finds that only about one‑third of seniors were treated even during the pandemic’s most intense waves. This shortfall is especially pronounced in the 65‑74 age bracket, where prescription rates lag behind those of older cohorts, suggesting that age alone does not drive prescribing behavior.

Several factors contribute to the low uptake. Primary‑care clinicians often cite limited time to assess eligibility, uncertainty about drug‑drug interactions, and concerns about rebound symptoms. Meanwhile, many older patients remain skeptical of antivirals, confusing them with vaccines or fearing side‑effects. Geographic disparities also play a role, with rural pharmacies reporting supply chain constraints and insurance coverage gaps that deter timely fills. Together, these barriers create a perfect storm that leaves a vulnerable population under‑treated despite clear clinical guidelines.

The public‑health implications are stark. Unaddressed, the treatment gap could translate into thousands of preventable hospitalizations and deaths each year, eroding the gains made by vaccination campaigns. Experts recommend a coordinated push that pairs antiviral prescribing alerts within electronic health records with targeted outreach campaigns aimed at seniors and their caregivers. Policy makers may also consider expanding Medicare coverage for antiviral courses and simplifying prescribing protocols. By closing the education and access loop, the health system can better leverage antivirals as a critical tool in the transition to endemic COVID‑19 management.